Tenofovir Disoproxil fumarate (Standard)
Based on 1 Customer Validation
Tenofovir Disoproxil (fumarate) (Standard) is the analytical standard of Tenofovir Disoproxil (fumarate). This product is intended for research and analytical applications. Tenofovir Disoproxil fumarate is a nucleotide reverse transcriptase inhibitor used to treat HIV and chronic Hepatitis B.
For research use only. We do not sell to patients.
- Purity : 99.65%
- CAS No.: 202138-50-9
- Formula: C23H34N5O14P
- Molecular Weight:635.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
-
HY-13910
Tenofovir -
HY-15232A
Tenofovir alafenamide fumarate -
HY-13782
Tenofovir Disoproxil fumarate -
HY-17427R
Emtricitabine (Standard) -
HY-B0250
Lamivudine -
HY-B0249
Didanosine -
HY-17392
Zalcitabine -
HY-17413
Zidovudine -
HY-17427
Emtricitabine -
HY-10570
Nevirapine -
HY-15232
Tenofovir alafenamide -
HY-13623A
Entecavir monohydrate
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 202138-50-9
-
Appearance Solid
-
Molecular Weight 635.51
-
Formula C23H34N5O14P
-
Color White to off-white
-
SMILES
O=C(OC(C)C)OCOP(OCOC(OC(C)C)=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)=O.O=C(O)/C=C/C(O)=O
-
Synonyms
Tenofovir DF (Standard); Bis(POC)-PMPA fumarate (Standard); GS 4331 fumarate (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Murphy RA, et al. Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity. Int J Mol Sci. 2017 Mar 1;18(3) [Content Brief]
[2]. Xu P, et al. Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro. J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692. [Content Brief]
[3]. Musumeci G, et al. M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. Sci Rep. 2017 Feb 1;7:41018 [Content Brief]
[4]. Wahl A, et al. Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. Sci Rep. 2017 Feb 1;7:41098 [Content Brief]
[5]. Menne S, Cote PJ, Korba BE, Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2005 Jul;49(7):2720-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tenofovir Disoproxil fumarate (Standard) Related Classifications
HY-13782R Related Classifications
Powered by Bioz